|
Statement of Purpose and Summary of Findings
This report is an update of two earlier
publications estimating the benefits and costs of the federal
governments efforts to reduce health care fraud. It
estimates the recoveries from government contractors associated
with health care fraud cases (the benefits) as well as the costs
incurred by federal agencies related to investigating and
prosecuting this fraud. Bipartisan efforts to reduce fraud led in
1986 to amendments strengthening the False Claims Act (FCA),
which establishes liability for contractors that commit fraud by
submitting false or fraudulent claims for reimbursement to the
federal government. These amendments enhanced the role of
whistleblowers, or individuals with inside information about
fraudulent practices of government contractors, facilitating
their ability to sue fraudulent contractors on behalf of the
federal government and increasing the amount of allowable
recoveries.
The False Claims Act and its whistleblower provisions have been particularly effective in the fight against Medicare fraud. Medicare, the federal governments second largest social program, spent $281 billion in 2003 for 41 million elderly and disabled Americans. In two previous studies conducted for Taxpayers Against Fraud (TAF) in 2001 and 2003, we found that anti-fraud efforts returned at least $8 for every $1 invested in health-related FCA enforcement activities. By far the most significant portion of the recoveries were attributable to FCA cases.
Because of increasing interest in the False Claims Act on the part of policymakers and the media, TAF requested that we update our study. Based on an analysis of data for the 5-year period FY 1999 FY 2003, we conclude that the U.S. taxpayers are getting a large and growing return on their dollars invested in fighting health care fraud. Specifically, federal government recoveries from civil health care fraud over this period totaled $5.7 billion; after deducting payments to whistleblowers, the net recoveries to the federal government amounted to $5.26 billion over the 1999-2003 period (See Figure 1). We estimate the governments costs over this five-year period to be $409.6 million. Thus, for every dollar spent to investigate and prosecute health care fraud in civil cases, the federal government receives nearly thirteen dollars back in return.
Figure 1 Benefits and Costs of
Federal Government Anti-Health Care Fraud Activities. FY
1999-2003 (in millions)

Why did the federal governments return on investment improve from nearly 9 to1 over the 1997-2001 period to nearly 13 to 1? This jump occurred because government recoveries in FY 2002 and FY 2003 increased far more rapidly than its enforcement costs. Civil health care fraud recoveries in FY 2002 and FY 2003 averaged $1.65 billion, up 38 percent from FY 2001 and more than double the level recovered in FY 2000. Government enforcement costs also increased and reached $104 million in 2003, but the overall estimated increase of about $30 million between 2001 and 2003 was not nearly as large as the gain in recoveries.

The benefit/cost ratio of nearly 13 to 1 is likely to underestimate the real return that the taxpayers are receiving on outlays for civil health care fraud enforcement. That is because, in addition to the actual monetary recoveries resulting from FCA investigations and prosecutions, there are also deterrent effects that affect the behavior of other firms in the industry. Major settlements with large recoveries have a ripple effect that reduces the likelihood of similar fraud against the Medicare program. These deterrent effects cannot be measured accurately, but they may be a substantial multiple of the direct, measurable benefits in the form of actual monetary recoveries.
Firms doing business with Medicare now realize that they have a great deal at stake when they fraudulently bill the federal government. As already noted, they may be liable for huge damages, which may be large enough to substantially weaken the firm if not bring it to its knees. Further, they may be excluded from participating in Medicare, which may have similar effects. In certain cases, corporate officials may be subject to criminal prosecution. Criminal investigations at DOJ sometimes parallel civil FCA investigations. These aspects of our methodology suggest that our estimates are likely to be on the conservative side.
The FCA and its whistleblower provisions are central to the federal governments anti-fraud efforts. They provide the federal government with the insider information it needs to uncover complex business fraud against Medicare and the clout it requires to recover stolen funds and deter future fraud. But the Department of Justice, which administers the FCA, must use its authority in a balanced manner. It must enforce the FCA with vigor, but it must also respect the rights of companies in the health care industry, continue to promote compliance plans that prevent fraud at the front end, and distinguish carefully between honest billing errors and fraud. If the provisions of the FCA are enforced in this fashion, it will continue to save large amounts of money for federal taxpayers and contribute to the financial viability of the Medicare program.
The 2004 report of the trustees of the
Medicare Trust Fund (MTF) indicates that the fund balance
depletion date has moved seven years closer in the past year.
Clearly, some difficult decisions will have to be made to assure
Medicares long-term solvency. In this situation, we cannot
afford a major drain on the Medicare program from fraud. Every
dollar that is siphoned off from the programs funding
sources by fraudulent billing practices makes the painful choices
we face even harder. If fraud is not curtailed, it will be paid
for by those enrolled in the program in the form of future
benefit cuts and by working-age people in the form of higher
taxes. Fraud will also be paid for by honest physicians,
hospitals, and other health care providers whose rates will be
further cut to help control the cost of the program. Each of
these partiesseniors, taxpaying workers, and health care
providershas a financial stake in curtailing health care
fraud.
The federal government needs strong
sanctions to deter health care fraud because the money at stake
can frequently be enormous. And because dishonest practices are
now very complex, sophisticated, and difficult to detect, the
government will continue to need the help of employees working
inside health care providers companies. Provisions of
current law empowering and protecting whistleblowers must be
maintained so that they can bring action against those
perpetrating fraud without fear of retaliation. Potential damages
must be large enough to matter to large corporations who could
brush aside or ignore small penalties.
This section presents the key findings of
this project. The report presents data on both recoveries and
costs over the five-year period from federal fiscal years 1999
through 2003. This period is selected to make the report as
current as possible. Some data for FY 2003 is not yet available
from the federal government, and we note some areas where we had
to make working estimates.
The report begins with the latest findings
on the federal governments recoveries from its work
in fighting health care fraud. We identify health care fraud
recoveries for each of the five fiscal years over the 1999-2003
period. The next step is to update the trends in the federal
governments costs in pursuing the perpetrators of
fraud. Here we estimate the costs incurred by the DOJs
Civil Division, the United States Attorneys Offices (USAOs), and
the Office of the Inspector General (OIG) at the U.S. Department
of Health and Human Services. This tells us how much the
taxpayers are laying out to obtain these recoveries. Finally,
these costs are compared to the benefits to demonstrate the
cost-effectiveness of the governments effort. What is the
bang for the buck emerging from governments
anti-fraud initiatives?
Our starting point is to estimate total
health-related civil fraud recoveries over the five-year period.
Over the 1999-2003 period, this amount equaled $5.7 billion. Some
$3.3 billion of this amount has been collected in the last two
years (see Figure 2).
Figure 2 Health-Related Civil Fraud
Recoveries Per Year, FYs 1999-2003 (in billions)
|

Source: U.S. Department of Justice
Savings of this magnitude can make a modest,
but significant contribution to the long-run solvency of this
vital program. This occurs because the bulk of the funds
recovered from successful investigations and prosecutions of
fraud are returned to the Medicare Trust Fund. (See Figure
3) In fact, the money returned to the trust fund greatly exceeds
the amount allocated to fighting health care fraud.
Figure 3 Total Funds Returned to the Medicare Trust Fund (MTF) versus Total Funds Appropriated from the MTF for Health Care Fraud Enforcement, FYs 1999-2002 (in millions)
|

* The figures for FY 2001 and 2002 are
approximate estimates of the amounts returned to the MTF. The
Department of Health and Human Services and the Department of
Justice Health Care Fraud and Abuse Control Program Annual Report
for FY 2001 notes that $1.3 billion was collected in 2001
and that more than $1 billion of the funds collected and
disbursed in 2001 were returned to the Medicare Trust Fund.
The same report covering FY 2002 notes that approximately
$1.4 billion was returned to the Medicare Trust Fund. The
corresponding figures for FY 2003 are not yet available.
Source: The Department of Health and
Human Services and the Department of Justice. Health Care
Fraud and Abuse Control Program. Annual Reports for FY
1999-2002.
What is the federal government spending to
achieve these results? Some staff and related costs are paid for
out of general revenues. But the more important source of funding
for both DOJ and OIG in HHS comes from allocations from the
Health Care Fraud and Abuse Control (HCFAC) program. HCFAC is a
national health care fraud prevention program set up under the
Health Insurance Portability and Accountability Act (HIPAA) of
1996. It is administered jointly by DOJ and HHS. HCFAC provides
an annual source of funds to DOJ and OIG to cover a portion of
their costs in fighting health care fraud through the enforcement
of the FCA. HCFAC established a special expenditure account with
annual appropriations from the Medicare Hospital Insurance Trust
Fund (MTF). Funds are disbursed annually from this account to
various divisions in DOJ and HHS to fund their anti-fraud
activities.
The first step in the estimate of costs is to determine the budget for the activities in DOJ that are directly involved in fighting fraud and generating recoveries. Two components of DOJ meet these criteriathe civil fraud enforcement activities of the Civil Division and the civil fraud litigation activities of the USAOs.
Table 1 DOJ/Civil Budget for Civil
Health Care Fraud Enforcement
Fiscal Years |
||||||
| |
1999 |
2000 |
2001 |
2002 |
2003 |
Five-year Total |
| Amount
spent on civil health care fraud enforcement (in
millions) |
$17.7 |
$17.2 |
$17.5 |
$18.0 |
$18.0 |
$88.4 |
Source: DOJ/Civil Division and the Economic and Social Research Institute.
Most USAOs have an Affirmative Civil
Enforcement (ACE) unit in their General Civil Litigation section
that investigates and prosecutes civil FCA cases. Civil fraud
litigation is not their only area of work, however, and there are
clearly cases outside of the health care field.
To estimate the USAO costs attributable to
combating health care fraud, we begin with the total USAO budget
over the five-year period. This amount is $6.976 billion. On
average, 22 percent of the budget went to Civil Litigation over
this period. Applying this percentage to the whole budget yields
an estimate of $1.535 billion for civil litigation by USAOs over
the 1999-2003 period.
The next step is to estimate how much of
this amount goes for civil fraud litigation. To obtain
this estimate, which does not appear in budget figures, we
interviewed several U.S. Attorneys offices. Amalgamating
their estimates yielded an approximate figure of 26 percent of
the salaries and related litigation costs of USAOs Civil
Litigation staff that is dedicated to civil fraud litigation (which,
according to the USAOs, is virtually 100 percent FCA
enforcement). This yields a dollar amount of $399.0 million for
the civil fraud budget of the USAOs over the 1999-2003
period. We assume that 65 percent of this amount was attributed
to fighting health care fraud in 1999-2001, and that the
corresponding proportion was 80 percent in 2002 and 2003. This
yields an estimate that $283.3 million was devoted to the USAO
activities in fighting health-care related civil fraud
litigation over the five-year period.
Table 2 shows the outlays for USAOs related to civil health care fraud.
Table 2 Amount Devoted to the USAO
Activities in Fighting Health-Care Related Civil Fraud
Litigation, Fiscal Years 1999-2003
Fiscal Years |
||||||
| |
1999 |
2000 |
2001 |
2002 |
2003 |
Five-year Total |
| USAOs
Costs (in millions) |
$42.2 |
$43.7 |
$47.0 |
$74.1 |
$76.3 |
$283.3 |
Source: U.S. Department of Justice, U.S. Attorneys Offices: Ten-Year Display of Budget Authority and Positions, 1995-2004. These numbers were calculated using the annul budget authority multiplied by 0.22. This number was then multiplied by 0.26. This number was then multiplied by 0.65 for 1999-2001, the estimated proportion of civil fraud litigation attributable to health care in those years, and by 0.8 for 2002 and 2003, the estimated proportion attributable to fraud in those years.
We now turn to estimating the costs
associated with civil fraud incurred at the Office of the
Inspector General at HHS. With the assistance of OIG, we
estimated the portion of their activity that could be
attributable to civil health care fraud
enforcement. The Department provided data on costs related to
civil health care fraud incurred in three areas: (1) the Office
of Investigations; (2) the Office of Audit Services; and (3) the
Office of Evaluations and Inspections. OIG calculated the number
of hours of work that their staff in each of these divisions
devoted to civil fraud enforcement, and also provided us with
fully loaded hourly rates of compensation reflecting not only
salaries but also employee benefits and overhead.[1]
Using these figures in our earlier report, we determined the
following total costs for each group of OIG employees in fiscal
year 2001:
Table 3 OIG Costs Related to Civil
Health Care Fraud Enforcement, Fiscal Year 2001
Office |
Costs (in millions) |
| Office
of Audit Services |
$4.98 |
| Office
of Investigations |
$3.32 |
| Office
of Evaluation and Inspections |
$.002 |
| Total |
$8.302 |
Source: OIG, HHS
Using this same methodology, we calculated
the OIG costs related to civil health care fraud for the other
four years in this study. OIG provided us with the data to make
the estimates for 2002 and 2003. We do not have similar data on
the OIG outlays related to civil fraud enforcement for 1999 and
2000. Therefore, we made the simplifying assumption that the
ratio of the actual outlays for civil health care fraud to the
HCFAC allocation to OIG observed in 2001 also applied to the two
earlier years.
Table 4 OIG Costs Attributable to
Civil Health Care Fraud and HCFAC Allocation to OIG, 1999-2003
(in millions)
Fiscal Years |
||||||
| |
1999 |
2000 |
2001 |
2002 |
2003 |
Five-year Total |
| OIG
Outlays for Civil Health Care Fraud |
$6.3 |
$7.6 |
$8.3 |
$6.2 |
$9.5 |
$37.9 |
Source: OIG, HHS. The numbers shown above for 1999 and 2000 are ESRI estimates reflecting the assumption that the proportion of the HCFAC allocation to OIG accounted for by civil health care fraud activities in 2001 also applied to these earlier years. The 2001-2003 numbers are based on actual OIG data.
We now sum the
costs from both DOJ and OIG to arrive at total federal government
costs for each of the five years in our study period.
Table 5
Federal Outlays for Civil Health Care Fraud Enforcement,
1999-2003 (in millions)
Fiscal
Years |
||||||
| |
1999 |
2000 |
2001 |
2002 |
2003 |
1999-2003 |
DOJ
Civil
|
$17.7 |
$17.2 |
$17.5 |
$18.0 |
$18.0 |
$88.4 |
| USAO |
$42.2 |
$43.7 |
$47.0 |
$74.1 |
$76.3 |
$283.3 |
| OIG
Outlays for Civil Health Care Fraud |
$6.3 |
$7.6 |
$8.3 |
$6.2 |
$9.5 |
$37.9 |
| Total |
$66.2 |
$68.5 |
$72.8 |
$98.3 |
$103.8 |
$409.6 |
We can now calculate the benefit/cost ratio.
To capture the governments net benefit, we need to first
remove the portion of the health-related FCA recoveries paid to
relators in qui tam cases. According to DOJ data,
relators were paid $438.9 million in health-related civil fraud
cases between 1999-2003.[2] Thus we remove
$438.9 million from the health-related civil fraud recoveries of
$5.7 billion. Therefore, the total amount of the recoveries
being returned to the government is $5.261 billion.
| |
Benefitsa |
Costsb |
Benefit-Cost
Ratio |
Estimate |
$5.261
billion |
$409.6
million |
12.84:1 |
a See Figure 4. 1999-2003 Total.
b See Table 5
Table
6 shows that the ratio of the federal governments direct
benefits from civil health care fraud enforcement to its costs is
12.84 to 1.
The U.S. taxpayers are getting an
excellent return on their dollars invested in fighting fraud
against the Medicare program. Our findings show that for every
dollar spent to investigate fraud, recover funds obtained through
illegal billings, and prosecute these civil cases, nearly
thirteen dollars are received in return. This order of magnitude
of the rate of return on the governments investment makes
this area of government expenditures unusual, if not unique.
Civil health care fraud is surely one area of the federal budget
where the government is running a substantial
surplus.
The benefit/cost ratio of nearly thirteen to
one is likely to be an underestimate of the real return that the
taxpayers are receiving on outlays for civil health care fraud
enforcement. The indirect benefits associated with deterrent
effects, described earlier, undoubtedly add substantially to the
publics benefit.
As a result of the higher stakes for health
care companies, many firms have become far more vigilant about
their internal operations in an effort to comply with the law.
Our earlier study concluded that firms are less likely to
threaten and intimidate employees who detect apparent fraudulent
billing practices now that they are aware that such employees
could become whistleblowers and be protected from corporate
retaliation. Administrative remedies are frequently implemented
by OIG in conjunction with FCA investigations and settlements
pursued by DOJ. One important area of collaboration between the
two federal agencies involves Corporate Integrity Agreements
(CIAs). These agreements are developed jointly by OIG and the
companies alleged to have committed fraud during FCA settlement
negotiations. CIAs are now part of most FCA settlements.[3]
During the course of our work on our
in-depth study of health care fraud, we uncovered many examples
of the deterrent effect emerging from the combined
activities of the federal government. In addition to the CIAs,
many of the consulting firms apparently switched from advising
companies how to beat the system to advising them on
how to comply with the letter of the law and stay out of trouble.
These indirect effects of the FCAs potentially large
settlements and its whistleblower provisions are important. If a
large settlement agreed to by one company not only changes
its behavior in the future, but also has a sentinel effect that
changes behavior throughout the industry, then the ripple effect
of the FCA is very widespread. The indirect effects, which cannot
be measured accurately at this time, may be a substantial
multiple of the direct, measurable benefits in the form of
monetary recoveries.
The government must use its authority with
both vigor and caution. The whistleblower and penalty provisions
of the law should be retained in order to provide the federal
government with the assistance it needs to uncover fraud and the
clout it requires to recover stolen funds. But it must also
respect the rights of companies in the health care industry,
continue to promote corporate agreements that deter fraud at the
front end, and distinguish carefully between honest billing
errors and fraud.
If the provisions of the FCA are enforced in this fashion, the Act will continue to save large amounts of money and contribute to the financial viability of the Medicare program.
[1] In calculating the staff and related costs attributable to civil health care fraud enforcement, OIG excluded certain cost items that are not relevant to our inquiry. These include criminal cases, employee misconduct cases, and grant fraud cases. Note that in some cases tracked as criminal cases, OIG staff may simultaneously be working on the civil fraud implications. OIG also excluded hours of work related to civil health care fraud undertaken in the general counsels office.
[2] The 1999-2002 figures were taken from the Monetary Results section of The Department of Health and Human Services and The Department of Justice. Health Care Fraud and Abuse Control Program Annual Reports for 1998-2002. The 2003 figure is an ESRI estimate.
[3] Meyer, Jack A. and Stephanie Anthony. Reducing Health Care Fraud: An Assessment of the Impact of the False Claims Act. September 2001. p. 25.